A. Sagrada

412 total citations
23 papers, 324 citations indexed

About

A. Sagrada is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, A. Sagrada has authored 23 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Cellular and Molecular Neuroscience and 4 papers in Physiology. Recurrent topics in A. Sagrada's work include Receptor Mechanisms and Signaling (11 papers), Ion channel regulation and function (7 papers) and Neuropeptides and Animal Physiology (7 papers). A. Sagrada is often cited by papers focused on Receptor Mechanisms and Signaling (11 papers), Ion channel regulation and function (7 papers) and Neuropeptides and Animal Physiology (7 papers). A. Sagrada collaborates with scholars based in Italy, Germany and Egypt. A. Sagrada's co-authors include Achille Schiavone, M.J. Fargeas, Lionel Buéno, Antonio Giachetti, R. Micheletti, Marco Turconi, Francesca Pagani, E. Giraldo, Helmut A. Ensinger and C.A. Rizzi and has published in prestigious journals such as Gastroenterology, Gut and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

A. Sagrada

23 papers receiving 292 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Sagrada Italy 12 142 133 80 78 68 23 324
B. R. Tuladhar United Kingdom 13 119 0.8× 121 0.9× 86 1.1× 140 1.8× 101 1.5× 19 394
E.S. Ellis United Kingdom 8 157 1.1× 132 1.0× 84 1.1× 84 1.1× 41 0.6× 9 325
Michel R. Briejer Belgium 9 107 0.8× 130 1.0× 101 1.3× 221 2.8× 122 1.8× 10 388
Gunilla Jedstedt Sweden 12 86 0.6× 68 0.5× 45 0.6× 101 1.3× 75 1.1× 18 319
M R Briejer Belgium 9 98 0.7× 107 0.8× 96 1.2× 249 3.2× 131 1.9× 10 408
Kay A. Wardle United Kingdom 11 165 1.2× 166 1.2× 93 1.2× 85 1.1× 43 0.6× 14 368
Eliana Messori Italy 8 79 0.6× 99 0.7× 72 0.9× 116 1.5× 58 0.9× 9 358
R. A. Borman United Kingdom 9 110 0.8× 76 0.6× 116 1.4× 209 2.7× 121 1.8× 11 389
R. Vickery United States 13 143 1.0× 121 0.9× 89 1.1× 162 2.1× 179 2.6× 23 523
L.G. Johnson Poland 8 140 1.0× 156 1.2× 54 0.7× 38 0.5× 70 1.0× 9 326

Countries citing papers authored by A. Sagrada

Since Specialization
Citations

This map shows the geographic impact of A. Sagrada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Sagrada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Sagrada more than expected).

Fields of papers citing papers by A. Sagrada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Sagrada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Sagrada. The network helps show where A. Sagrada may publish in the future.

Co-authorship network of co-authors of A. Sagrada

This figure shows the co-authorship network connecting the top 25 collaborators of A. Sagrada. A scholar is included among the top collaborators of A. Sagrada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Sagrada. A. Sagrada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weiser, Thomas, Michael Brenner, Angelo Ceci, et al.. (1999). BIIR 561 CL: A Novel Combined Antagonist of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors and Voltage-Dependent Sodium Channels with Anticonvulsive and Neuroprotective Properties. Journal of Pharmacology and Experimental Therapeutics. 289(3). 1343–1349. 8 indexed citations
2.
Sagrada, A., et al.. (1995). 5-Hydroxytryptamine3 receptor antagonists inhibit enterotoxin B-induced emesis in the ferret. Pharmacological Research. 31. 188–188. 1 indexed citations
3.
Sagrada, A., et al.. (1994). Antagonistic properties of McNeil‐A‐343 at 5‐HT4 and 5‐HT3 receptors. British Journal of Pharmacology. 113(3). 711–716. 6 indexed citations
4.
Rizzi, C.A., A. Sagrada, Achille Schiavone, et al.. (1994). Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn-Schmiedeberg s Archives of Pharmacology. 349(4). 338–345. 20 indexed citations
5.
Brambilla, A., Wolfram Gaida, Klaus Mendla, et al.. (1994). Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders. European Journal of Drug Metabolism and Pharmacokinetics. 19(3). 179–183. 6 indexed citations
6.
Sagrada, A., et al.. (1994). Himbacine discriminates between putative muscarinic M1 receptor-mediated responses. Life Sciences. 54(17). PL305–PL310. 11 indexed citations
7.
Sagrada, A., et al.. (1994). New pyrrolidin-, piperidin- and azepin-2-oxocarboxylic acid esters are preferential M1, M3 muscarinic antagonists. Synthesis and bronchospasmolytic activity. European Journal of Medicinal Chemistry. 29(6). 411–421. 4 indexed citations
8.
Ensinger, Helmut A., H. N. Doods, G. Lambrecht, et al.. (1993). WAL 2014 - A muscarinic agonist with preferential neuron-stimulating properties. Life Sciences. 52(5-6). 473–480. 35 indexed citations
9.
Sagrada, A., et al.. (1993). Himbacine discriminates between two M1 receptor-mediated responses. Life Sciences. 52(5-6). 574–574. 4 indexed citations
10.
Giraldo, E., et al.. (1992). DAU 6285: A novel antagonist at the putative 5-HT4 receptor. Life Sciences. 51(8). 583–592. 26 indexed citations
11.
Turconi, Marco, A. Sagrada, E. Montagna, et al.. (1991). Pharmacological properties of a novel class of 5-HT3 receptor antagonists. European Journal of Pharmacology. 203(2). 203–211. 22 indexed citations
12.
Sagrada, A., Marco Turconi, P Schiantarelli, et al.. (1991). Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. Cancer Chemotherapy and Pharmacology. 28(6). 470–474. 9 indexed citations
13.
14.
Schiavone, Achille, A. Sagrada, Francesca Pagani, & Antonio Giachetti. (1989). Role of muscarinic receptor subtypes in the regulation of migrating myoelectric complex in the dog. Gastroenterology. 96(1). 116–121. 27 indexed citations
15.
Sagrada, A., et al.. (1989). Cimetropium Bromide: In vitro and in vivo Evaluation of Spasmolytic Activity on Human and Dog Colon. Digestion. 42(3). 143–150. 11 indexed citations
16.
Schiavone, Achille, A. Sagrada, R. Micheletti, & Antonio Giachetti. (1988). Pharmacological characterization of muscarinic receptors involved in McN‐A‐343‐induced effects on intestinal motility and heart rate in conscious dogs. British Journal of Pharmacology. 94(2). 566–572. 17 indexed citations
17.
Pagani, Francesca, A. Sagrada, A. Brambilla, Sylvain Brunet, & Antonio Giachetti. (1988). A model for studying saliva secretion in the conscious dog.. PubMed. 291. 253–62. 1 indexed citations
18.
Sagrada, A., et al.. (1987). N-butyl hyoscine exerts local spasmolytic effect in the small and large bowel of the conscious dog.. PubMed. 287(2). 237–47. 9 indexed citations
19.
Sagrada, A., M.J. Fargeas, & Lionel Buéno. (1987). Involvement of alpha-1 and alpha-2 adrenoceptors in the postlaparotomy intestinal motor disturbances in the rat.. Gut. 28(8). 955–959. 51 indexed citations
20.
Schiavone, Achille, et al.. (1985). Cimetropium: characterization of antimuscarinic and spasmolytic properties.. PubMed. 35(5). 796–9. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. R. Tuladhar Breakdown of academic impact, for papers by E.S. Ellis Breakdown of academic impact, for papers by Michel R. Briejer Breakdown of academic impact, for papers by Gunilla Jedstedt Breakdown of academic impact, for papers by M R Briejer Breakdown of academic impact, for papers by Kay A. Wardle Breakdown of academic impact, for papers by Eliana Messori Breakdown of academic impact, for papers by R. A. Borman Breakdown of academic impact, for papers by R. Vickery Breakdown of academic impact, for papers by L.G. Johnson
Rankless by CCL
2026